Summary: In one of the largest human studies on this topic to date, researchers report that raising dopamine levels with the precursor L-DOPA modestly increased people’s willingness to wait for larger, delayed rewards. On average, participants became about 20% less impulsive under L-DOPA than under placebo. The results challenge earlier small-sample studies that linked dopamine enhancement to greater impulsivity, and instead indicate dopamine supports patience and valuation of future outcomes.
Using computational cognitive models, the team found no evidence that dopamine altered basic decision mechanics such as processing speed, information accumulation, or decision caution. The pattern points to dopamine changing how future rewards are valued across time, rather than changing the mechanics of making a choice. These findings refine our understanding of dopamine’s role in self-control, with potential implications for addiction and other conditions involving dysregulated reward processing.
Key Facts
- Reduced impulsivity: L-DOPA increased participants’ willingness to wait for larger delayed rewards by roughly 20% compared with placebo.
- Stable decision processes: No credible effects on decision speed, evidence accumulation, or response caution were observed—dopamine affected valuation of future rewards rather than decision mechanics.
- Relevance to addiction: Results help explain how altered dopamine signalling may contribute to impulsive choices seen in substance use and behavioural addictions.
Source: University of Cologne
Overview of the study
A research team in the Psychology Department at the University of Cologne, led by Dr. Elke Smith and Professor Jan Peters, ran a large, carefully controlled study examining how increasing dopamine affects temporal discounting—the tendency to prefer smaller immediate rewards over larger delayed ones. Dopamine is a key neurotransmitter involved in reward, motivation and decision-making, and previous studies produced mixed results, partly because many had small sample sizes.
In a randomised, double-blind, placebo-controlled within-subject design, 76 healthy adults (male and female) completed choices between smaller immediate and larger delayed monetary rewards after receiving either L-DOPA, a dopamine precursor that raises central dopamine availability, or placebo. The large sample and preregistered analysis helped reduce the risk of false positive findings and allowed the team to examine individual difference factors that might shape drug responses.
Participants displayed the established “magnitude effect”: larger rewards were discounted less steeply over time than smaller rewards. Across the sample, L-DOPA produced a reliable though modest reduction in temporal discounting—participants were somewhat more willing to wait for larger delayed rewards under L-DOPA than under placebo.
Importantly, the investigators applied hierarchical Bayesian computational modelling, specifically a non-linear temporal discounting drift diffusion model, to separate valuation processes from choice mechanics. L-DOPA’s effect appeared on parameters tied to how future rewards are valued rather than on parameters reflecting evidence accumulation speed, response caution, or non-decision time. In other words, dopamine shifted subjective valuation of delayed outcomes instead of altering the speed or caution of decisions.
The team also tested several commonly used behavioural and cognitive proxies that have been proposed to index baseline dopamine function—working memory capacity, spontaneous eye-blink rate, and self-reported impulsivity—to see whether these measures moderated drug effects. They found no convincing evidence that these proxies predicted individual differences in response to L-DOPA, calling into question their validity as direct markers of baseline dopamine across the circuits relevant to temporal discounting.
“Our findings show that L-DOPA increases humans’ willingness to wait for rewards, providing new evidence that challenges some earlier influential studies conducted in relatively small samples,” says Dr. Elke Smith. “Measures such as working memory, blink rate, or questionnaire-based impulsivity may capture meaningful differences between people, but they do not appear to map straightforwardly onto baseline dopamine levels that determine drug response.”
These results improve understanding of dopaminergic mechanisms that guide intertemporal choice and offer a clearer framework for interpreting impulsive decision-making in disorders where dopamine signalling is altered, including addiction. Future research should test how these pharmacological effects generalise to clinical populations and whether interactions with hormonal or other physiological fluctuations modify dopamine’s effects on decision-making.
Key Questions Answered:
A: Increasing dopamine with L-DOPA made participants less impulsive on average, increasing their willingness to wait for larger future rewards.
A: Earlier, smaller studies reported inconsistent effects, sometimes finding increased impulsivity. This larger, preregistered study observed a modest reduction in impulsive choice under L-DOPA.
A: The findings clarify dopamine’s role in valuing future rewards and may help explain impulsive choices in substance use and behavioural addictions, informing potential treatment directions.
About this dopamine and neuroscience research news
Author: Eva Schissler
Source: University of Cologne
Contact: Eva Schissler – University of Cologne
Image credit: Neuroscience News
Original Research: Closed access. “Dopamine and temporal discounting: revisiting pharmacology and individual differences” by Elke Smith et al., Journal of Neuroscience.
Abstract
Dopamine and temporal discounting: revisiting pharmacology and individual differences
Altered dopamine (DA) neurotransmission is commonly associated with changes in how people discount future rewards. Pharmacological manipulations in healthy individuals have produced mixed effects on temporal discounting, with both increases and decreases reported. These inconsistencies may reflect meaningful individual differences in drug response or false positives from small samples.
To address these issues, the authors revisited L-DOPA’s effects on temporal discounting in a larger sample of 76 healthy participants and evaluated several putative proxy measures for baseline DA function. Using hierarchical Bayesian computational models, the data in both drug conditions were best described by a non-linear temporal discounting drift diffusion model. Consistent with some recent animal and human work, L-DOPA produced a reliable, small reduction in discounting rate. The study found no credible evidence that the candidate proxy measures moderated this drug effect, questioning their utility as direct indicators of baseline dopamine in this context.